Sixth Street Partners, a global investment firm, led a $830m funding round in Caris Life Sciences, an innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine. Funds and accounts advised by T. Rowe Price Associates, Silver Lake, Fidelity Management & Research, and Coatue were significant participants in the round. Additional investors included Columbia Threadneedle Investments, CPPIB, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Management, Pura Vida Investments and First Light Asset Management. All existing investors from the 2020 financing participated in this deal along with a number of new investors. "The strong participation of all our existing, as well as new investors, is a testament to the promise of the Caris platform and supports our leading position as the most innovative company in the precision medicine space," Brian J. Brille, Caris Life Sciences Vice Chairman.